Previous close | 40.19 |
Open | 40.39 |
Bid | 40.37 x 110000 |
Ask | 40.72 x 110000 |
Day's range | 40.31 - 40.62 |
52-week range | 34.00 - 44.69 |
Volume | |
Avg. volume | 1,448 |
Market cap | 9.059B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 28.70 |
EPS (TTM) | 1.41 |
Earnings date | 06 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | 1.18 (2.91%) |
Ex-dividend date | 30 Jan 2024 |
1y target est | 47.55 |
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
Review Qiagen's (QGEN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher